Letter

New prostate cancer drug

Prostate cancer’s day in the sun

BMJ 2008; 337 doi: 10.1136/bmj.a1249 (Published 11 August 2008)
Cite this as: BMJ 2008;337:a1249

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Gerhardt Attard, clinical research fellow1,
  2. Alison H Reid, clinical research fellow1,
  3. David Dearnaley, consultant clinical oncologist1,
  4. Johann S De Bono, consultant medical oncologist1
  1. 1Institute for Cancer Research, Royal Marsden NHS Foundation Trust, Sutton SM2 5PT
  1. gerhardt.attard{at}icr.ac.uk

    Recently we and others have studied different anti-cancer drugs in patients with castration resistant prostate cancer (CRPC), including HER2 targeting drugs, pan-ErbB inhibitors, histone deacetylase inhibitors, anti-angiogenics, a survivin antisense, and several new cytotoxics.1 2 In none of these trials have we observed anything like the biochemical, radiological, and, importantly, symptomatic benefit reported with abiraterone acetate.

    The results of our phase I study have been confirmed by a second phase I study in North America and four phase II studies run by …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular